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The management of biliary tract cancer (BTC) has deeply 
changed in the past decade. Just few years ago patients 
with advanced disease had no effective treatment options 
but supportive therapy. Palliative chemotherapy was often 
administered in the absence of evidence of efficacy, as no 
randomized studies were available.
At present the results of two randomized trials have 
established a new standard of therapy: the combination 
of gemcitabine and platinum compounds has proven to 
significantly prolong survival in unresectable patients (1,2). 
Moreover, the development of new therapeutic modalities, 
including pioneering targeted therapies, is opening new 
avenues in the management of BTC (3). Undoubtedly, this 
represents a timely subject, considering the steps that have 
been made in different cancer types by adding newer agents. 
Some phase II studies with targeted agents, mainly anti-EGFR 
and VEGF drugs, are now available with equivocal results.
If we look at the current knowledge on the molecular basis 
of BTC, the EGFR pathway seems to fit the prerogatives 
to be a good setting for targeted agents. The incidence of 
biological features that might predict response or resistance 
to anti-EGFR has been studied in preclinical models.
EGFR gene amplifications are detected in approximately 
6% of BTC, and EGFR mutations only in 15% (4) 
suggesting that the majority of patients may lack a biologic 
requisite of sensitivity to small molecules inhibitors.
On the contrary, KRAS mutations, that are now a 
validated predictive factor of response to anti-EGFR 
antibodies in colorectal cancer, occur in 6% to 52% of BTC, 
being more common in eastern than western countries.
In phase II studies anti-EGFR antibodies cetuximab 
or panitumumab, associated to chemotherapy produced 
impressive results in terms of response rate in KRAS wild 
type patients (5,6). Because of the design of these non-
randomized studies, it is impossible to define the real impact 
of the addiction of monoclonal antibodies to chemotherapy.
More definitive results were expected from randomized 
studies: however the lack of molecular selection of patients 
might have blunted the results.
Lee et al. designed a phase III trial in which 268 patients 
with unresectable cholangiocarcinoma (CC), gallbladder 
carcinoma (GBC) and ampullary carcinoma (AC) were 
randomized to receive either gemcitabine-oxaliplatin 
(GEMOX) alone or in combination with erlotinib as first 
line treatment (7). The primary endpoint was progression-
free survival (PFS). Although a trend in favor of the regimen 
GEMOX-erlotinib was observed, the study did not meet 
the primary endpoint; the median PFS was 4.2 months in 
patients who received chemotherapy only versus 5.8 months 
in those who had chemotherapy plus erlotinib (P=0.087). The 
overall survival (OS) was 9.5 months in both treatment arms. 
It is noteworthy that the addition of erlotinib statistically 
improved the objective responses (ORs) (P=0.005). This 
was especially evident in patients with CC. This subgroup 
had a benefit in PFS as well, even though this difference was 
marginally significant (P=0.049). On these bases, the authors 
suggested that patients with CC might benefit more from the 
addition of erlotinib to chemotherapy. 
At the latest ASCO meeting Malka et al. presented similar 
data from their randomized phase II trial of GEMOX with 
or without cetuximab (8). The primary endpoint of a better 
4-months PFS for the cetuximab-containing regimen was 
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met (63% vs. 53%), but data on median PFS and median 
OS showed no difference between treatment arms. 
Both trials had a simple design of 2 arms phase III or 
phase II, multicenter, open-label studies. The number of 
patients was adequate to distinguish differences between 
treatment arms, but in Lee’s trial there was an imbalanced 
distribution of type of primary tumor, due to the choice 
of stratification factors. Moreover, the data on subgroups 
were then obtained retrospectively; in our opinion this 
issue is quite relevant, as many studies suggest a different 
biology and chemosensitivity between GBC and CC, so 
stratification on location is highly recommended.
Some consideration must be made about the rationale of 
both studies. Lee and collegues motivated their choice of the 
combination treatment on the basis of a single agent phase 
II trial of erlotinib (9) and on the results of erlotinib therapy 
in pancreatic cancer (10). No phase II randomized trials of 
GEMOX ± erlotinib has ever been made. Tissue analysis was 
possible only in few cases, making any conclusion on data for 
KRAS and EGFR subgroups simply hazardous. 
Background for cetuximab therapy seems to be more 
solid; a couple of reports and phase II trials (5,6) have shown 
interesting results. Subgroup analysis for KRAS status and 
site of primary is under way; when available, Malka work 
might be exploratory for a larger phase III trial.
Thus, at present, studies without patient selection should 
be regarded as preliminary.
Even though OS in metastat ic  disease has  not 
significantly improved with the introduction of anti-
EGFR therapy, the possibility to obtain higher response 
rates, if compared to chemotherapy alone, rises the 
chance to consider the role of these treatments as part of a 
neoadjuvant program. In the phase II study of Gruenberger 
with cetuximab in combination with GEMOX, a conversion 
from unresectable to resectable disease was obtained in 30% 
of cases (5). 
A recent case report has shown how treatment can be 
driven by knowledge of molecular status; on the basis of 
HER2 expression investigators proposed a 4th line therapy 
with trastuzumab and paclitaxel in a patient affected by CC, 
obtaining an impressing response (11). Small phase II trials 
in BTC with anti HER2 agents, in the absence of selection 
on gene expression, had previously shown no activity (12). 
The identification of newer pathways in carcinogenesis 
and progression, such as SRC or ROS (13,14), could pave 
the way for the introduction of other targeted drugs. If the 
molecular status is not helpful we should not forget that fit 
patients might benefit from multi-drugs chemotherapy, as it 
was proven for pancreatic cancer (15).
The issue of how to improve treatment by adding 
targeted agents is highly relevant; we firmly believe that 
the history of BTC can be changed if we detect the specific 
pathway that is activated in every single patient. 
Therefore, what we have learnt from more common 
malignancies should not be forgotten when designing new 
clinical trials on BTC; small, well-designed phase II trials 
might be more relevant than large inconclusive phase III 
studies.
Patients should be then selected on the basis of gene 
expression; this is the only way we can make our treatment 
really “targeted”.
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